Journal of Central Nervous System Disease · Nov 18, 2026

Blood-Based Biomarkers for Alzheimer’s Disease: Advances in Peripheral Biomarkers for Early Diagnosis and Disease Monitoring

By Sampurna FR, Kusuma OZK, Wicaksono AW et al.

Alzheimer’s disease (AD) is a slowly progressive neurodegenerative disorder in which neuropathological alterations develop long before the onset of clinically recognizable cognitive impairment, creating a prolonged preclinical phase that presents a critical opportunity for early intervention. Although cerebrospinal fluid (CSF) biomarker analysis and amyloid positron emission tomography (PET) remain the current diagnostic standards, their invasive procedures, high costs, and limited accessibility restrict their widespread application in routine clinical settings, underscoring the need for more practical and scalable diagnostic approaches. In recent years, blood-based biomarkers have gained considerable attention as minimally invasive alternatives capable of facilitating early diagnosis and longitudinal disease monitoring. The most extensively studied biomarkers include the plasma amyloid-β (Aβ) 42/40 ratio, phosphorylated tau isoforms (p-tau181, p-tau217, and p-tau231), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), each reflecting distinct yet complementary pathological mechanisms of AD, including amyloid plaque deposition, tau-related neurofibrillary pathology, neuronal and axonal degeneration, and astrocyte-mediated neuroinflammation. Furthermore, emerging biomarkers such as neuron-derived extracellular vesicles and lipid metabolism–associated markers may provide additional insights into neuronal dysfunction and metabolic disturbances that contribute to disease susceptibility and progression. Collectively, these peripheral biomarkers offer a promising, cost-effective, and easily accessible strategy for improving early detection, tracking disease progression, and evaluating therapeutic responses; however, their routine clinical implementation continues to be challenged by the need for assay harmonization, validation across ethnically and geographically diverse populations, and the establishment of standardized, clinically meaningful diagnostic thresholds. Future research should therefore focus on large-scale multicenter validation studies and the integration of multimarker panels to improve diagnostic accuracy and facilitate the translation of blood-based biomarkers into routine clinical practice.

doi.org/10.1177/11795735261509659Biomarkers

AgingResearch.News